Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 7, 1996
Issued Date -
N/A
app pub date -
Oct 7, 1993
filing date -
Aug 22, 1991
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully